Foamix Celebrates Receiving 20th US Patent

Foamix Ltd. recently announced the United States Patent and Trademark Office has granted US Patent No. 8,512,718, Pharmaceutical Composition For Topical Application, describing, inter alia, unique Oil-Gel compositions, which can be used in combination with therapeutic agents. These compositions, which primarily comprise hydrophobic solvents, are suitable for the delivery of a broad range of pharmaceutical agents targeting various diseases and disorders of the skin and the eye.

“We are delighted to have reached this landmark of 20 issued US patents, which is a major achievement and a reflection of the excellent work by Foamix’s dedicated professional patent team and our proactive policy to provide intellectual property protection for Foamix’s platform technologies and pharmaceutical product pipeline,” said Dr. Dov Tamarkin, Foamix’s CEO.

Foamix now holds the following US patents: US 8,512,718, US 8,486,376, US 8,486,375, US 8,486,374, US 8,435,498, US 8,362,091, US 8,343,945, US 8,119,150, US 8,119,109, US 8,119,106, US 8,114,385, US 7,820,145, US 7,704,518, US 7,700,076, US 7,682,623, US 7,645,803, US 7,575,739, US 6,994,863, US 6,967,023, and US 6,911,211.

As a technology leader, Foamix collaborates with multinational and local pharmaceutical companies in the development of unique topical products. Foamix’s versatile patent-protected OilGel and foam platforms enable the development of topical drugs with greater efficacy, favorable safety, and higher convenience profiles.

Foamix Ltd. is a clinical-stage, privately held specialty pharmaceutical company focused on the development of proprietary topical foams and OilGel products for dermatology, gynecology, as well as ophthalmic disorders. The company’s lead product, Minocycline Foam, is the first-ever topical minocycline that can be used for the treatment of acne, rosacea, and skin infections. Foamix’s current Phase II study has shown its Minocycline Foam to be a safe and effective topical treatment and an alternative to oral antibiotics, with superior efficacy and no significant side effects.

Minocycline, a well-known broad-spectrum antibiotic, is taken mainly for the treatment of acne, available only in oral dosage form. Foamix believes that a topical Minocycline foam could capture a significant portion of the oral anti-acne and anti-rosacea drug market, currently worth over $1 billion per annum, as it offers high efficacy with a favorable safety profile.

To date, Foamix has 55 granted patents worldwide, including the 20 issued patents in the US. Additionally, the company has more than 135 pending patent applications worldwide, of which over 70 applications are filed in the US. As a technology leader in its field, Foamix collaborates with multinational and local pharmaceutical companies, in the development of patent-protected, unique topical products using its versatile patent protected platforms. For more information, visit www.foamix.co.il.